55,366 Shares in Sionna Therapeutics, Inc. (NASDAQ:SION) Acquired by TD Asset Management Inc

Key Points

• TD Asset Management Inc acquired 55,366 shares of Sionna Therapeutics, Inc. valued at approximately $579,000, increasing its ownership to 0.13% as per the latest SEC filing.
• In a disappointing earnings report, Sionna Therapeutics reported an EPS of (-0.62), missing analysts' expectations of (-0.45) by $0.17.
• Jennison Associates LLC also purchased a new stake in Sionna Therapeutics during the first quarter, valued at $8,995,000, indicating strong interest from institutional investors in the company.

TD Asset Management Inc bought a new stake in Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 55,366 shares of the company's stock, valued at approximately $579,000. TD Asset Management Inc owned 0.13% of Sionna Therapeutics as of its most recent SEC filing.

Separately, Jennison Associates LLC purchased a new stake in shares of Sionna Therapeutics in the 1st quarter valued at $8,995,000.

Sionna Therapeutics Stock Up 1.2%

NASDAQ:SION opened at $17.12 on Tuesday. The business's 50-day simple moving average is $17.23. Sionna Therapeutics, Inc. has a 1 year low of $7.26 and a 1 year high of $25.19.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).

Analyst Ratings Changes

Separately, Wall Street Zen downgraded Sionna Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Insider Buying and Selling

In related news, major shareholder Tpg Gp A, Llc acquired 60,000 shares of Sionna Therapeutics stock in a transaction on Friday, June 27th. The stock was purchased at an average cost of $15.84 per share, with a total value of $950,400.00. Following the purchase, the insider directly owned 6,744,962 shares in the company, valued at approximately $106,840,198.08. The trade was a 0.90% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.90% of the stock is currently owned by corporate insiders.

Sionna Therapeutics Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

Want to see what other hedge funds are holding SION? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.